[The extratumor mechanisms of osteolysis in multiple myeloma and the means for their correction].
In 70 patients with stage III multiple myeloma (MM) the authors studied spontaneous and lipopolysaccharide-induced production of interleukin-1 (IL-1) and interleukin-6 (IL-6) by blood and bone marrow mononuclear cells, concentration of parathyroid hormone and vitamin D3 in the serum. Bone marrow density was measured at photon absorption (Gambro), in patients treated with osteoprotectors bonefos and oxidevit before and after therapy (3.5-6 month course). It is shown that in MM there is a pathogenetic association between production of osteotropic IL-1, IL-6 and bone demineralization. The cases with reduced concentration of Ca and P ions in the serum (4 and 5.7% of patients, respectively) and increased PTH concentration (7%) suggest the existence of new, extratumor mechanisms of osteolysis. It is found that biphosphonates are optimal osteoprotectors. Bonefos (chlodronat, Lieras, Finland) arrests osteolysis proved by a significant increase of bone marrow density and clinical effect.
Golenkov
A K
AK
Lutskaia
T D
TD
Kliushnenkova
E N
EN
Tishenina
R S
RS
Valiulina
L S
LS
Novikov
V E
VE
Mitina
T A
TA
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D001853:Bone Marrow / Q000737:chemistry; D002762:Cholecalciferol / Q000097:blood; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007375:Interleukin-1 / Q000032:analysis; D015850:Interleukin-6 / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy* / Q000378:metabolism; D010014:Osteolysis / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism; D010281:Parathyroid Hormone / Q000097:blood
D007375:Interleukin-1; D015850:Interleukin-6; D010281:Parathyroid Hormone; D002762:Cholecalciferol; D006909:Hydroxyproline